Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCAGN01876 with Immune Therapies in Advanced Malignancies
NCT03126110Phase 2Completed
- Sponsor
- Incyte
- Start
- Apr 2017
- Primary completion
- Nov 2021
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, open-label trial of INCAGN1876 in solid tumor (advanced stage), metastatic solid tumor, Cervical Cancer (CC) and 3 more (6 arms), sponsored by Incyte. Primary endpoints: Treatment-emergent Adverse Events up to 27.4 months and Objective Response Rate up to 44.7 months. Started Apr 2017; status: completed.
02
Drugs
INCAGN1876
03
Conditions
solid tumor (advanced stage)metastatic solid tumorCervical Cancer (CC)gastric cancer (GC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03126110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03126110.